Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lasya releases new cosmetic cream
dA, formulated by the company, is said to be effective in reducing the appearance of age spots, freckles, and other skin imperfections besides enhancing the appearance of overall
dA, formulated by the company, is said to be effective in reducing the appearance of age spots, freckles, and other skin imperfections besides enhancing the appearance of overall
Ensemblins are a new class of synthetic macrocycles developed by Ensemble using its chemistry platforms, including DNA-Programmed Chemistry. Macrocyclic rings are found in many natural product-based drugs and
CCX354 is a potent and selective inhibitor of CCR1, a chemokine receptor that drives the recruitment of inflammatory cells into the joints of patients with rheumatoid arthritis (RA).
PF-05280602 is an engineered variant of recombinant human Factor VIIa which is said to provide improved acute and prophylactic treatment for hemophilia A & B patients with inhibitors.
AZD1446 is a selective modulator of the alpha4beta2 neuronal nicotinic receptor that arose out of a research collaboration conducted by Targacept and AstraZeneca. As per the research and
Bristol-Myers Squibb is said to benefit from BT by deriving greater value from its network services through increased standardization and innovation. The contract extension covers all Bristol-Myers Squibb
McKesson Strategic Supply Sourcing is believed to give providers enhanced visibility and control over their medical-surgical supply spending. The solution also has the ability to support multiple materials
The grant has been provided as part of the ‘5050 Plan’ that aims to incentivize and assist start-up, technology-based companies within HHTZ, Hangzhou, Zhejiang Province. HHTZ director Sheng
The KDM-1102 drug is a new sublingual formulation of propanolol whose formulation development is now completed and can be produced in large volume. The sublingual formulation is designed
According to the company, the Phase III trial will be a randomized, prospective, multi-site, double-blind, placebo-controlled, parallel-group study of C-Topical Solution as an anesthetic prior to a diagnostic